【レポートの概要（一部）】
1. Report Overview
1.1 Multiple Sclerosis Drugs Market Overview
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by this Report
1.5 Who is this Report for?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQ)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to Multiple Sclerosis
2.1 What is Multiple Sclerosis?
2.1.1 Key Statistics: 2.5 Million Sufferers in the World
2.2 The Pathology of MS
2.2.1 Symptoms
2.3 Diagnosis of MS
2.3.1 Tests for MS Include These Technologies
2.4 Measuring MS
2.5 The Different Types of MS
2.5.1 Relapsing-Remitting MS (RRMS)
2.5.2 Secondary Progressive MS
2.5.3 Progressive Relapsing MS
2.5.4 Primary Progressive MS
2.5.5 Other Presentations of the Disease
2.6 Possible Causational Factors for MS
2.6.1 Genetic Factors
2.6.2 Infection
2.6.3 Environmental Factors and Less Well-Supported Theories
2.7 Demographics and Geographical Distribution
2.8 Different Treatments for MS
3. Leading Multiple Sclerosis Drugs
3.1 Copaxone (glatiramer acetate) by Teva Pharmaceutical Industries
3.1.1 First Non-Interferon Immunomodulator
3.1.2 Teva and the Approval of Generic Competition
3.1.3 The First Generic is Approved – Sandoz’s Glatopa
3.1.4 Industry Surprised by Copaxone’s Solid Sales, Despite Generic Competition: 40mg Dose is Key
3.1.5 Patents on Copaxone 40mg Being Contested – Although Teva Receives Good News in Europe
3.1.6 Copaxone Revenues 2011-2015
3.1.7 Copaxone Revenue Forecast 2016-2026
3.2 Tecfidera (dimethyl fumarate) by Biogen
3.2.1 Rapidly Grown Since 2013 to Become the Leading Oral MS Therapy
3.2.2 Tecfidera Revenues 2013-2015
3.2.3 Tecfidera Revenue Forecast 2016-2026
3.3 Avonex (interferon beta-1a) by Biogen
3.3.1 The Leading Interferon Therapy
3.3.2 Avonex Revenues 2011-2015
3.3.3 Patent Extension to 2026
3.3.4 Avonex Revenue Forecast 2016-2026
3.4 Gilenya (fingolimod) by Novartis
3.4.1 The First Oral Disease-Modifying Drug for MS
3.4.2 US Patent Trial and Appeal Board Sides Against Novartis
3.4.3 Gilenya Revenues 2011-2015
3.4.4 Gilenya Revenue Forecast 2016-2026
3.5 Rebif (interferon beta-1a) by Merck KGaA
3.5.1 Merck Attempting to Differentiate Rebif from Other Interferon Therapies
3.5.2 Rebif Revenues 2011-2015
3.5.3 Rebif Revenue Forecast 2016-2026
3.6 Tysabri (natalizumab) by Biogen
3.6.1 High Efficacy Offsets the Risks
3.6.2 Tysabri Revenues 2011-2015
3.6.3 Tysabri Revenue Forecast 2016-2026
3.7 Betaseron / Betaferon (interferon beta-1b) by Bayer
3.7.1 First Disease Modifying Drug for MS
3.7.2 Betaseron Revenues 2011-2015
3.7.3 Betaseron Revenue Forecast 2016-2026
3.8 Aubagio (teriflunomide) by Sanofi
3.8.1 More than 48,000 Patients Treated
3.8.2 Aubagio Revenues 2014-Q1 2016
3.8.3 Aubagio Revenue Forecast 2016-2026
3.9 Plegridy (peginterferon beta-1a) by Biogen
3.9.1 36% Reduction in ARR compared to Placebo
3.9.2 Plegridy Revenues 2014-2015
3.9.3 Plegridy Revenue Forecast 2016-2026
3.10 Lemtrada (alemtuzumab) by Sanofi
3.10.1 Very Effective, but with Side Effects
3.10.2 Lemtrada Past Revenues and Revenue Forecast 2016-2026
4. Multiple Sclerosis Drugs Pipeline 2016-2026
4.1 Ocrelizumab (Ocrevus / RG1594) by Roche
4.1.1 Humanised mAb Targeting CD20
4.1.2 First Drug to Receive Breakthrough Therapy Designation for MS
4.1.3 Exciting Latest Results from Two Phase 3 Trials
4.1.4 Ongoing Clinical Trials
4.1.5 Ocrelizumab Revenue Forecast 2016-2026
4.2 Ozanimod by Celgene
4.2.1 S1PR Modulator
4.2.2 Promising Results from Phase 2 RADIANCE Study
4.2.3 Ongoing Clinical Trials
4.2.4 Ozanimod in MS Revenue Forecast 2018-2026
4.3 Zinbryta (daclizumab high-yield process) by Biogen and AbbVie
4.3.1 Humanised mAb Being Jointly Developed by two Giants
4.3.2 Positive Opinion on Marketing Authorisation from the CHMP
4.3.3 Zinbryta Revenue Forecast 2016-2026
4.4 Ofatumumab by Novartis
4.4.1 Novartis Acquires Full Remaining Rights in $1bn Agreement
4.4.2 Advantages and Disadvantages over Ocrelizumab
4.5 Ponesimod by Actelion
4.5.1 S1PR Modulator
4.5.2 Positive Earlier Results
4.6 Laquinimod by Teva and Active Biotech
4.6.1 Troubled Oral Immunomodulator
4.6.2 Turned Down for European Licence
4.7 MED1003 by MedDay
4.7.1 Unique Method of Action
4.7.2 Results from MS-SPI and MS-ON
4.8 Masitinib by AB Science: Phase 3 and has Completed a Futility Analysis
4.9 Siponimod (BAF312) by Novartis: Competitor for Gilenya
5. Global Multiple Sclerosis Drugs Market 2016-2026
5.1 Global Multiple Sclerosis Drugs Market Forecast 2016-2026
5.2 What Factors Will Drive Growth in the Global MS Drugs Market?
5.2.1 Growth of Existing Products, Reaching Peak Blockbuster Revenues before Patent Expiry
5.2.2 Exciting New Products Due to be Launched Within the Next Ten Years
5.2.3 Premium Prices, Accompanied by Price Increases
5.2.4 Prevalence and Incidence of Multiple Sclerosis is Increasing
5.2.5 Unmet Needs and Strategic Partnering
5.3 What Factors will Restrain Growth in the Global MS Drugs Market?
5.3.1 Multiple Patent Expiries on Leading Drugs will Lead to Generic and Biosimilar Competition
5.3.2 Declining Healthcare Budgets Could Lead to Cost Pressures
5.3.3 Crowded Marketplace
6. Leading Therapeutic Segments: Revenue Prospects, 2016-2026
6.1 The Main Therapeutic Segments within the MS Drugs Market, Forecast 2016-2026
6.2 Therapeutic Composition of the Market in 2015, 2020 and 2026
6.3 Monoclonal Antibodies Segment Forecast 2016-2026
6.4 S1PR Modulator Segment Forecast 2016-2026
6.5 Interferons Segment Forecast 2016-2026
6.6 Other Immunomodulators Segment Forecast 2016-2026
6.7 ‘Others’ Segment Forecast 2016-2026
7. National Markets for MS Drugs: Revenue Prospects, 2016-2026
7.1 Multiple Sclerosis Cases and Prevalence Values
7.2 Leading Regional Markets Forecast 2016-2026
7.2.1 Regional Composition of the Market in 2015, 2020 and 2026
7.3 US MS Drugs Market
7.3.1 Reasons why the US Market Dominates the MS Drugs Market to Such an Extent
7.3.2 Undergoing Some Changes
7.3.3 US MS Drugs Market Forecast 2016-2026
7.4 EU5 MS Drugs Market 2016-2026
7.4.1 Common Characteristics of all the EU5 Nations in Regards to MS Drugs and Drivers of Growth
7.4.2 German MS Drugs Market: Leading EU Market
7.4.2.1 German MS Drugs Market Forecast 2016-2026
7.4.3 French MS Drugs Market: Strong Healthcare System
7.4.3.1 French MS Drugs Market Forecast 2016-2026
7.4.4 UK MS Drugs Market
7.4.4.1 UK MS Drugs Market Forecast 2016-2026
7.4.5 Italian MS Drugs Market
7.4.5.1 Italian MS Drugs Market Forecast 2016-2026
7.4.6 Spanish MS Drugs Market
7.4.6.1 Spanish MS Drugs Market Forecast 2016-2026
7.5 Canadian MS Drugs Market: Country has Highest Rate of MS in the World
7.5.1 Canadian MS Drugs Market Forecast 2016-2026
7.6 Japanese MS Drugs Market Forecast 2016-2026
7.7 Chinese MS Drugs Market Forecast 2016-2026
7.8 Indian MS Drugs Market Forecast 2016-2026
8. Conclusions from Our Research and Analysis
8.1 How will Revenues Change over the Forecast Period?
8.2 How will the Therapeutic Composition of the Market Change?
8.3 How will National Markets Develop from 2016 to 2026?
8.4 Concluding Remarks
【レポート販売概要】
■ タイトル：多発性硬化症治療薬の世界市場および研究開発展望2016-2026■ 英文：Multiple Sclerosis Drugs Market and R&D Outlook 2016-2026
■ 発行日：2016年6月
■ 調査会社：visiongain
■ 商品コード：VGAIN60619
■ 調査対象地域：グローバル
- 世界主要国における淋疾検査市場2015The report presents a detailed analysis of the Gonorrhea diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Gonorrhea definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals - Com …
- ジストニア(Dystonia)：世界の治験レビュー（2015年上半期版）Dystonia Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Dystonia Global Clinical Trials Review, H1, 2015" provides data on the Dystonia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Dystonia. It includes an overview of the trial numbers and their recruitment status as per the site of trial condu …
- データセンター・コロケーションサービスの世界市場予測（～2020）MarketsandMarkets forecast the data center colocation market size to grow from USD 25.70 Billion in 2015 to USD 54.13 Billion by 2020, at a compound annual growth rate (CAGR) of 16.1%. Increasing adoption of cloud computing has led the organizations to upgrade to the upcoming technological solutions, such as modular data center infrastructure and virtualization for data center. This acts as a prim …
- イギリスの注射器・注射針市場見通し（～2021）United Kingdom Syringes and Needles Market Outlook to 2021 Summary GlobalData’s new report, "United Kingdom Syringes and Needles Market Outlook to 2021", provides key market data on the United Kingdom Syringes and Needles market. The report provides value, in millions of US dollars, volume (in units) and average price data (in US dollars), within market segments - General Syringes and Specialized …
- グローバルスマートフォン販売動向（通信市場レポート）Summary 'Smartphone Sales to Reach 1.9bn in 2018 as ASP Drops below $190,' a new Research in Focus report by Pyramid Research, covers the global handset market, focusing on handsets. It was generated by combining Pyramid analysis with information gathered from operators, vendors, and other industry players as well as primary and secondary research from filings, press releases and regulatory bodies …
- バックヒートシール装置の世界市場2016-2020About Bag Heat Sealing Equipment Bag heat sealing equipment is used in sealing plastic material bags and pouches. Sealing of packaging products safeguards the products, checks their stability throughout the supply chain, and resists changes in temperature to maintain their quality and hygiene, thereby increasing the shelf life. Bag heat sealing equipment is used in the food, pharmaceutical, person …
- クラウドベースPBXの世界市場2017-2021About Cloud Based PBX A cloud-based private branch exchange (PBX) system works on cloud computing technology in which data are stored and transferred through the Internet instead of using a computer or any other hardware. Cloud technology has become popular among consumers with the introduction of programs such as MobileMe and iCloud. These are consumer-based cloud computing technologies. Technavi …
- ドラッグデリバリー技術の世界市場Drug delivery technology market offers a promising approach for the delivery of drugs through various routes of administration. Drug delivery technology is aimed at maximizing the drug delivery at the targeted site so as to increase the efficiency of drug and proposing improved patient compliance. The major factors responsible for the growth of the drug delivery technology market are the rising pr …
- 世界の非小細胞肺癌(NSCLC)治療薬市場Lung cancer has become one of the most prevalent cause of cancer related morbidity and mortality in past several decades across the world. Lungs are a pair of spongy tissues present in the thoracic cavity responsible for gaseous exchange from the surrounding environment. These tissues could be easily damaged by the toxins present in environment and cells may show cancerous growth upon longer expos …
- BRIC新興国の心調律管理(CRM)処置動向（～2020）BRIC Cardiac Rhythm Management (CRM) Procedures Outlook to 2020 Summary GlobalData’s new report, "BRIC Cardiac Rhythm Management (CRM) Procedures Outlook to 2020", provides key procedures data on the BRIC Cardiac Rhythm Management (CRM) Procedures. The report provides procedure volumes within market categories – Implantable Cardioverter Defibrillator (Single and Dual Chamber ICD) Procedures, Cardi …
- トルエン（メチルベンゼン）の世界市場：ベンゼン、溶媒、キシレン、TDI用途About Toluene Toluene, also known as methylbenzene, is an aromatic hydrocarbon, which contains seven carbon and eight hydrogen atoms, and it is represented by the formula C7H8. Toluene is produced during the manufacture of gasoline by naphtha reforming. Reformate accounts for more than 70 percent of the world’s toluene production with the rest coming from pygas. It is a clear, colorless liquid wit …
- 消費者用ネットワークアタッチトストレージ（NAS）の世界市場分析The global consumer NAS market is expected to reach USD 8.20 billion by 2025, according to a new report by Grand View Research, Inc. Globally growing demand for efficient data backup systems, speedy data transfer, and cost-effective storage systems are some of the key drivers for the consumer network attached storage market. Home segment is one of the largest segment in 2016 and is expected to mai …
- 軍用ヘリコプタMRO（整備・修理・分解点検）の世界市場2016-2020About Military Helicopter MRO Helicopter maintenance, repair, and overhaul (MRO) has become one of the essential practices to ensure that fleets have optimal airworthiness and an extended service life. MRO companies perform functions such as repairs, inspections, routine checks, and overhaul. The operators and OEMs are strictly governed by national and international aviation regulatory bodies, suc …
- マルチアクセスエッジコンピューティングの世界市場展望2017-20276According to Stratistics MRC, the Global Multi Access Edge Computing Market is accounted for $2,811.18 million in 2017 and is expected to reach $32,221.78 million by 2026 growing at a CAGR of 31.1% during the forecast period. IT and telecom network convergence, base station evolution and continually improving server capacity are the factors driving the growth of this market. However, security and …
- 悪性胸水(Malignant Pleural Effusion)：世界の治験レビュー2014年下半期版Malignant Pleural Effusion Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Malignant Pleural Effusion Global Clinical Trials Review, H2, 2014" provides data on the Malignant Pleural Effusion clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Malignant Pleural Effusion. It includes an overview of the t …
